FDA grants breakthrough device designation to BioPrax™ biofilm disruption device

Published October 23, 2019

Print

Biospace was one of several media outlets to report on UB partner company Garwood Medical Devices, which has been granted a “Breakthrough Devices” designation that will expedite review of the company’s BioPrax™ device by the FDA.

BioPrax, developed to treat biofilm infections on prosthetic knee implants, was created using technology licensed from UB.

The electrical stimulation method that BioPrax uses was developed through a multidisciplinary collaboration between the labs of UB engineering and medical researcher Mark Ehrensberger and UB medical researcher Anthony Campagnari, a SUNY Distinguished Professor.

Read the story here.

Stories also appeared in Science & Enterprise and NS Medical Devices